ReviewEuroasian journal of hepato-gastroenterology
Non-celiac Gluten Sensitivity: A New Clinical Entity or Growing Controversy?
Review in Euroasian journal of hepato-gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Psychiatric Symptoms Associated with Non-Celiac Gluten Sensitivity: A Focused Narrative Review.Nutrients · 2026Review
- Gluten Tolerance through Microbial and Cultural Adaptation: A Holistic Model for Celiac Disease and Non-celiac Gluten Sensitivity.Euroasian journal of hepato-gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims and background: Non-celiac gluten sensitivity (NCGS) has become an increasingly recognized condition, yet its diagnostic framework remains vague. Unlike celiac disease, NCGS lacks specific biomarkers and relies heavily on self-reported symptoms. Despite this ambiguity, the gluten-free product market reached USD 20.1 billion in 2021 and is projected to exceed USD 26.5 billion by 2030, indicating widespread adoption beyond medically justified use. Results: Emerging evidence suggests that gluten may not be the sole trigger in NCGS. Other wheat components, including amylase-trypsin inhibitors (ATIs), wheat germ agglutinin (WGA), and fructans, may contribute to symptom generation. Accordingly, the term "non-celiac wheat sensitivity (NCWS)" is increasingly preferred. Studies also show that low-FODMAP diets can alleviate symptoms attributed to NCGS, complicating the diagnostic distinction from irritable bowel syndrome (IBS) and other disorders of gut-brain interaction (DGBIs). The presence of antigliadin antibodies (AGA) or HLA-DQ2/DQ8 haplotypes may suggest predisposition, but these are neither specific nor diagnostic for NCGS. Conclusion: The lack of standardized diagnostic criteria and the influence of the nocebo effect pose significant challenges in the clinical assessment of NCGS. Self-reported outcomes alone are insufficient for a reliable diagnosis. Clinical significance: The unwarranted adoption of gluten-free diets in individuals without confirmed gluten-related disorders may lead to nutritional imbalance and disruption of the gut microbiota. Until validated diagnostic tools are established, clinicians should evaluate suspected NCGS cautiously, considering differential diagnoses and evidence-based dietary guidance. How to cite this article: Bektaş A. Non-celiac Gluten Sensitivity: A New Clinical Entity or Growing Controversy? Euroasian J Hepato-Gastroenterol 2025;15(2):170-172.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.